News

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...